NCT07132684

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

A Multicenter, Randomized, Controlled Clinical Trial Comparing VA and D/IA Induction Regimens in Elderly Patients With Acute Myeloid Leukemia Suitable for Intensive Chemotherapy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 55 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.

Conditions

• AML, Adult

Interventions

Type	Name	Description
DRUG	Daunorubicin/Idarubicin	Daunorubicin/Idarubicin is used in Induction Therapy and Maintenance Therapy.
DRUG	Cytarabine	Cytarabine is used in Induction Therapy, Consolidation Therapy and Maintenance Therapy.
DRUG	Azacitidine	Azacitidine is used in VA regimen
DRUG	Venetoclax	Venetoclax is used in VA regimen

Timeline

• Start date: 2025-08-31
• Primary completion: 2027-08-30
• Completion: 2028-08-30
• First posted: 2025-08-20
• Last updated: 2026-03-02

Locations

1 site across 1 country: China